2024
Expanding artificial intelligence to understudied populations: congenital heart disease as the next frontier
Oikonomou E, Khera R. Expanding artificial intelligence to understudied populations: congenital heart disease as the next frontier. European Heart Journal 2024, ehae737. PMID: 39523016, DOI: 10.1093/eurheartj/ehae737.Commentaries, Editorials and LettersCongenital heart diseaseHeart disease
2021
Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication A Meta-Analysis
Antonopoulos A, Angelopoulos A, Papanikolaou P, Simantiris S, Oikonomou E, Vamvakaris K, Koumpoura A, Farmaki M, Trivella M, Vlachopoulos C, Tsioufis K, Antoniades C, Tousoulis D. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication A Meta-Analysis. JACC Cardiovascular Imaging 2021, 15: 460-471. PMID: 34801448, DOI: 10.1016/j.jcmg.2021.09.014.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseVascular inflammationInflammatory biomarkersRisk stratificationPrognostic valueClinical risk factorsNet clinical benefitValue of biomarkersUse of biomarkersMeasurement of biomarkersMeta-regression analysisLack of reportingCardiovascular eventsCohort studyStable patientsEvent incidenceRisk prognosticationClinical benefitHeart diseaseRisk factorsRisk discriminationClinical practiceInflammationSuch biomarkersMeta-Analysis
2017
Stem Cell Therapy for Congenital Heart Disease
Tsilimigras DI, Oikonomou EK, Moris D, Schizas D, Economopoulos KP, Mylonas KS. Stem Cell Therapy for Congenital Heart Disease. Circulation 2017, 136: 2373-2385. PMID: 29229621, DOI: 10.1161/circulationaha.117.029607.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCongenital heart diseaseCell therapyHeart diseaseClinical trialsGold standard treatment modalityHypoplastic left heart syndromePulmonary artery hypertensionRight ventricle dysfunctionStandard treatment modalityAlternative treatment optionLarge clinical studiesStem cell deliveryQuality of lifeCell-based therapeutic strategiesArtery hypertensionStem cell-based therapeutic strategiesVentricle dysfunctionSurgical palliationVolume overloadHeart syndromeSafety profileCell-seeded graftsCochrane LibraryTreatment optionsTreatment modalitiesEfficacy of ganglionated plexi ablation in addition to pulmonary vein isolation for paroxysmal versus persistent atrial fibrillation: a meta-analysis of randomized controlled clinical trials
Kampaktsis PN, Oikonomou EK, Y. Choi D, Cheung JW. Efficacy of ganglionated plexi ablation in addition to pulmonary vein isolation for paroxysmal versus persistent atrial fibrillation: a meta-analysis of randomized controlled clinical trials. Journal Of Interventional Cardiac Electrophysiology 2017, 50: 253-260. PMID: 28887742, DOI: 10.1007/s10840-017-0285-z.Peer-Reviewed Original ResearchConceptsPulmonary vein isolationAT/AFGP ablationAtrial fibrillationPV isolationVein isolationPlexi ablationAF patientsAtrial tachyarrhythmiasSubtype of AFSignificant structural heart diseaseParoxysmal AF patientsVentricular ejection fractionParoxysmal atrial fibrillationPersistent atrial fibrillationStructural heart diseaseSustained atrial fibrillationPersistent AF patientsClinical trial dataNon-significant trendPrimary endpointAF subtypesAtrial sizeEjection fractionHeart disease